 HOPKINTON, Mass., Nov. 02, 2020 GLOBE NEWSWIRE -- Spring Bank Pharmaceuticals, Inc. Nasdaq: SBPH, a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced an upcoming trial-in-progress poster presentation for SB 11285 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer SITC 2020, to be held virtually from November 9-14, 2020. SB 11285 is Spring Banks intravenously IV-administered STING agonist product candidate that is currently being evaluated in a Phase 1a1b clinical trial as a monotherapy and in combination with Roches PD-L1 checkpoint inhibitor Tecentriq. This poster presentation will include an update on the progress of the IV SB 11285 Phase 1a1b trial. 